Fig. 6
From: Assay establishment and validation of a high-throughput organoid-based drug screening platform
Validation of a high-throughput organoid imaging assay by testing the chemosensitivity of tumor organoids. A Presentation of organoids that are sensitive or resistant to 5-FU (10 μM). D0 refers to the day of drug treatment and d10 means the tenth days post-d0. B, C The survival rate and total area of tumor organoids on day 10 after 5-FU treatment. The d0 count was set as the standard. A total of 176 organoids were measured in the 5-FU-sensitive group and 150 organoids were measured in the 5-FU-resistant group. D Presentation of organoids that are sensitive or resistant to CPT11 (10 μM). E, F The survival rate and total area of tumor organoids on day 10 after CPT-11 treatment. A total of 188 organoids were measured in the CPT-11-sensitive group, and 180 organoids were measured in the CPT-11-resistant group. Data are presented as the mean \(\pm\) SD